I've got another analogy you might like! When you drop a frog into a boiling pot, he jumps out, however, if you start it on a low simmer and then slowly turn up the heat, he never realizes he's being boiled! The stove is still on low heat here!!
"We continue to build the body of clinical evidence supporting our Precision Cancer Monitoring platform, with several clinical utilities demonstrated in recently reported studies," stated Mark Erlander, Ph.D., chief scientific officer of Trovagene. "These utilities include the ability to determine response to therapy, identify disease progression earlier than cancer imaging, monitor for minimal residual disease after surgery, stratify patients according to baseline mutation load, and act as an alternative to invasive and costly biopsy procedures. We currently have five urine-based tests available to clinicians for the assessment of known driver mutations such as BRAF, KRAS and EGFR, which can be critical for precisely managing a patient's cancer."
June 1, 2015, 8:00 – 11:30 a.m. EDT Poster Display
June 1, 2015, 3:00 – 4:15 p.m. EDT Poster Discussion
Prognostic Value of Plasma Circulating Tumor (ct) DNA KRAS Mutations and Serum CA19-9 in Unresectable Pancreatic Cancer (PC) Patients
Poster Discussion Session: Gastrointestinal (Noncolorectal) Cancer
Collab./Presenter: Herlev Hospital, U. of Copenhagen, Trovagene/Vlada Melnikova, M.D., Ph.D.
May 31, 2015, 8:00 – 11:30 a.m. EDT
Low frequency KRAS G12/13 mutations in urine cell-free (cf) DNA from patients with BRAF V600E-mutant advanced cancers
Poster Session: Tumor Biology
Collaborator/Presenter: Filip Janku, M.D., Ph.D., MD Anderson Cancer Center
June 1, 2015, 8:00 – 11:30 a.m. EDT
Kinetic Monitoring of EGFR T790M in Urinary Circulating Tumor DNA Predicts Radiographic Progression and Response in Patients with Metastatic Lung Adenocarcinoma
Poster Session: Lung Cancer – Non-Small Cell Metastatic
Collaborator/Presenter: Hatim Husain, M.D., University of California San Diego - Moores Cancer Center
June 1, 2015, 8:00 – 11:30 a.m. EDT
Monitoring minimal residual disease (MRD) by KRAS mutation burden in urinary or plasma circulating tumor (ct) DNA in colorectal cancer (CRC) patients with resectable liver metastases
Poster Session: Gastrointestinal (Colorectal) Cancer
Collaborators/Sponsor: Genomac Research Institute and Trovagene/Cecile Rose Vibat, Ph.D.
Why wouldn't somebody take a flier at AKAO at these levels? $100M with over $60M in cash? Seems like a no brainer? It was off my radar until today ... If you liked it at $10, you must love it at $5 and change? What am I missing?
If you're talking antibiotics .. have you noticed that FOMX placed a successful secondary at $9.50 and never looked back? Breaking out after their ER yesterday ... they burned thru more cash, but I think the market could be huge for their topical antibiotic treatment for acne. fwiw
Their timeline really got pushed out! Hence, the fall from grace?
On a slow day ... I know there were a few people on the IDRA board that were following FOMX, as well. It's another Baker Bros. "under the radar" company in the antibiotic space. I've been in a small position since the $8's and was totally surprised at how positive the market was to recent secondary pricing and follow thru. Very low floater, like TROV. FOMX message board is nearly non-existent. Was just curious what some thought about the ER ... apparently, the market likes it!
Just how much more blood do they think they can possibly squeeze out of this stone? Agree with OWT's analogy to holding a bomb ... the risk-reward clearly is on the side of people holding long here.
Gee, I don't know why I get a mental image when I see your name "plunge"!!
No, they probably accomplished their mission ... got their clients IN a couple $$ lower!
How do you know that? NEJM is a big deal ... please cite source!
Shorts and MMs in cahoots controlling this in a .20 range with nearly 300K shares traded? Normally, any volume creates volatility in one direction or the other ... This nearly 1M volume in 2 days should have catapulted this thing above $18!! Tick tock!!
It was out yesterday a.m., wasn't it?
Gee, what's "wrong" here? Over 500K in volume mostly above $11 after a big move and the market was red most of the day? We have some serious accumulation!!!